Abstract
Cannabis is widely used recreationally and for symptomatic relief in a number of ailments. However, cannabis has been implicated as a risk factor for the development of psychotic illness. For forty years researchers have utilised intravenous preparations of Δ9- THC, as well as several other phytocannabinoids, in a laboratory setting. The intravenous route has the most reliable pharmacokinetics, reducing inter-individual variation in bioavailability and is well suited for the delivery of synthetic compounds containing a sole pharmacological moiety. Given the association between cannabinoids and psychotic illness, there has been a resurgence of interest in experimental studies of cannabinoids in humans, and the intravenous route has been employed. Here in a critical review, we appraise the major findings from recent intravenous cannabinoid studies in humans and trace the historical roots of this work back to the 1970’s.
Keywords: Cannabis, Intravenous, delta-9-tetrahydrocannabinol, delta-9-tetrahydrocannabivarin, cannabidiol, THC, psychotic illness, phytocannabinoids, pharmacokinetics, intravenous route.
Current Pharmaceutical Design
Title:Cannabis in the Arm: What Can we Learn from Intravenous Cannabinoid Studies?
Volume: 18 Issue: 32
Author(s): Amir Englund, James M. Stone and Paul D. Morrison
Affiliation:
Keywords: Cannabis, Intravenous, delta-9-tetrahydrocannabinol, delta-9-tetrahydrocannabivarin, cannabidiol, THC, psychotic illness, phytocannabinoids, pharmacokinetics, intravenous route.
Abstract: Cannabis is widely used recreationally and for symptomatic relief in a number of ailments. However, cannabis has been implicated as a risk factor for the development of psychotic illness. For forty years researchers have utilised intravenous preparations of Δ9- THC, as well as several other phytocannabinoids, in a laboratory setting. The intravenous route has the most reliable pharmacokinetics, reducing inter-individual variation in bioavailability and is well suited for the delivery of synthetic compounds containing a sole pharmacological moiety. Given the association between cannabinoids and psychotic illness, there has been a resurgence of interest in experimental studies of cannabinoids in humans, and the intravenous route has been employed. Here in a critical review, we appraise the major findings from recent intravenous cannabinoid studies in humans and trace the historical roots of this work back to the 1970’s.
Export Options
About this article
Cite this article as:
Englund Amir, M. Stone James and D. Morrison Paul, Cannabis in the Arm: What Can we Learn from Intravenous Cannabinoid Studies?, Current Pharmaceutical Design 2012; 18 (32) . https://dx.doi.org/10.2174/138161212802884618
DOI https://dx.doi.org/10.2174/138161212802884618 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inflammation and Mood Disorders: Proinflammatory Cytokines and the Pathogenesis of Depression
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Immune-Glutamatergic Dysfunction as a Central Mechanism of the Autism Spectrum Disorders
Current Medicinal Chemistry Pediatric Acute-onset Neuropsychiatric Syndrome and <i>Mycoplasma Pneumoniae</i> Infection: A Case Report Analysis with a Metabolomics Approach
Current Pediatric Reviews Role of Wnt Signaling in Tissue Fibrosis, Lessons from Skeletal Muscle and Kidney
Current Molecular Medicine Anionic Host Defence Peptides from the Plant Kingdom: Their Anticancer Activity and Mechanisms of Action
Protein & Peptide Letters Disentangling the Intricacies of Migraine: A Review
CNS & Neurological Disorders - Drug Targets Antipsychotics for the Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD)
Current Neuropharmacology Fragment-Based Development of HCV Protease Inhibitors for the Treatment of Hepatitis C
Current Computer-Aided Drug Design The Glucocorticoid Analog Dexamethasone Alters the Expression and the Distribution of Dopamine Receptors and Enkephalin within Cortico- Subcortical Regions
Current Molecular Pharmacology The Vitamin D Saga: Breaking Dawn
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Potential Drugs Targeting Microglia: Current Knowledge and Future Prospects
CNS & Neurological Disorders - Drug Targets Small Molecule Antagonists of the Tachykinin NK2 Receptor [General Reviews]
Mini-Reviews in Medicinal Chemistry AMPK As A Target in Rare Diseases
Current Drug Targets Illicit Methylphenidate Use: A Review of Prevalence, Availability, Pharmacology, and Consequences
Current Drug Abuse Reviews The Impact of AD Drug Treatments on Event-Related Potentials as Markers of Disease Conversion
Current Alzheimer Research Design and Development of Nanovehicle-Based Delivery Systems for Preventive or Therapeutic Supplementation with Flavonoids
Current Medicinal Chemistry The Remote Monitoring of Smoking in Adolescents
Adolescent Psychiatry Cognitive Impairment and Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Peripheral Biomarkers to Assess Suicide Risk
Current Psychiatry Reviews Spatial Correlations between the Vacuolation, Prion Protein (PrPsc) Deposits and the Cerebral Blood Vessels in Sporadic Creutzfeldt-Jakob Disease
Current Neurovascular Research